Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options

During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review,...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Arpita, Menon, Smitha P., Dy, Grace K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850130/
https://www.ncbi.nlm.nih.gov/pubmed/27144064
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008
_version_ 1782429621012135936
author Desai, Arpita
Menon, Smitha P.
Dy, Grace K.
author_facet Desai, Arpita
Menon, Smitha P.
Dy, Grace K.
author_sort Desai, Arpita
collection PubMed
description During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway.
format Online
Article
Text
id pubmed-4850130
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-48501302016-05-03 Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options Desai, Arpita Menon, Smitha P. Dy, Grace K. Cancer Biol Med Review During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in EGFR and translocations in ALK and ROS1 have identified subsets of patients with excellent tumor response to oral targeted agents with manageable side effects. In this review, we highlight treatment options including corresponding clinical trials for oncogenic alterations affecting the receptor tyrosine kinases MET, FGFR, NTRK, RET, HER2, HER3, and HER4 as well as components of the RAS-RAF-MEK signaling pathway. Chinese Anti-Cancer Association 2016-03 /pmc/articles/PMC4850130/ /pubmed/27144064 http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008 Text en Copyright 2016 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Desai, Arpita
Menon, Smitha P.
Dy, Grace K.
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title_full Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title_fullStr Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title_full_unstemmed Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title_short Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options
title_sort alterations in genes other than egfr/alk/ros1 in non-small cell lung cancer: trials and treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850130/
https://www.ncbi.nlm.nih.gov/pubmed/27144064
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0008
work_keys_str_mv AT desaiarpita alterationsingenesotherthanegfralkros1innonsmallcelllungcancertrialsandtreatmentoptions
AT menonsmithap alterationsingenesotherthanegfralkros1innonsmallcelllungcancertrialsandtreatmentoptions
AT dygracek alterationsingenesotherthanegfralkros1innonsmallcelllungcancertrialsandtreatmentoptions

Ejemplares similares